Memorial Sloan Kettering Cancer Center: Mesothelioma, Malignant trials

The registry lists 17 Mesothelioma, Malignant studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 9Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Sacituzumab Govitecan in People With MesotheliomaRecruitingNCT06477419Phase 2
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaRecruitingNCT06057935Phase 2
• Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural MesotheliomaRecruitingNCT06037941Not applicable
• Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant MesotheliomaCompletedNCT03399552Phase 1/2Results posted
• Pevonedistat Alone and in Combination With Chemotherapy in Patients With MesotheliomaTerminatedNCT03319537Phase 1/2Results posted
• Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2Results posted
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaCompletedNCT00398138Phase 1Results posted
• A Study of Pembrolizumab and Cryoablation in People With MesotheliomaCompletedNCT05071014Phase 1
• A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaActive, not recruitingNCT04897022Phase 1
• Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaActive, not recruitingNCT04577326Phase 1
• A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaActive, not recruitingNCT04162015Phase 1
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedNCT04040231Phase 1
• Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural MesotheliomaWithdrawnNCT02639767Phase 1
• Clinical and Histopathologic Characteristics of BAP1 MutationsCompletedNCT01773655
• Psychosocial Needs and Exploration of Online Support for Patients With MesotheliomaCompletedNCT01356251Not applicable
• Alanosine in Treating Patients With CancerCompletedNCT00062283Phase 2
• Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by SurgeryCompletedNCT00005636Phase 3